Literature DB >> 20573444

Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells.

Eun Uk Jung1, Jung-Hwan Yoon, Youn-Jae Lee, Jeong-Hoon Lee, Bo Hyun Kim, Su Jong Yu, Sun Jung Myung, Yoon Jun Kim, Hyo-Suk Lee.   

Abstract

Hypoxia may activate survival signals in cancer cells. Moreover, hypoxic cells are less sensitive than normoxic cells to doxorubicin cytotoxicity, a potent activator of the p53 tumor suppressor gene. N-myc downstream-regulated gene-1 (NDRG1) is a hypoxia- and retinoic acid-inducible protein, and has been previously implicated in carcinogenesis. As this protein is also a downstream target of p53 and hepatocellular carcinoma (HCC) cells frequently evidence resistance to retinoic acid (RA) cytotoxicity, we attempted to determine whether the suppression of NDRG1 expression may sensitize HCC cells to doxorubicin and/or RA cytotoxicity. HCC cells expressed NDRG1 protein, and the expression of this protein was hypoxia- and RA-inducible. Doxorubicin treatment induced HCC cell cytotoxicity via the activation of mitochondrial apoptotic signals, including caspase-9 activation. Hypoxic HCC cells are less sensitive to doxorubicin-induced apoptosis. The suppression of NDRG1 expression either by siRNA or flavopiridol sensitized hypoxic HCC cells to doxorubicin cytotoxicity, and this was attributed to more profound augmentation of JNK and caspase-9 activation. The suppression of NDRG1 expression also sensitized RA-resistant HCC cells to RA-induced apoptosis, and this sensitization was more apparent in hypoxic HCC cells than in normoxic cells. Glutaredoxin2 expression was down-regulated in NDRG1-suppressed HCC cells. These results show that hypoxia- and RA-inducible NDRG1 expression is responsible for doxorubicin and RA resistance in HCC cells. Thus, the selective interruption of NDRG1 signaling may prove to be therapeutically useful in HCCs, particularly in the advanced infiltrative type of tumors exposed to hypoxic environments.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20573444     DOI: 10.1016/j.canlet.2010.05.020

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  24 in total

1.  NDRG1/Cap43 overexpression in tumor tissues and serum from lung cancer patients.

Authors:  D Wang; X Tian; Y Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-22       Impact factor: 4.553

2.  Expression of N-myc downstream-regulated gene 1 in primary gallbladder carcinoma and its correlation with clinicopathological features and clinical outcome.

Authors:  Sheng-bin Zhang; Shi-peng Song; Bing Li; Yong-sheng Zhou; Yang-de Zhang
Journal:  Med Oncol       Date:  2011-07-07       Impact factor: 3.064

Review 3.  Novel approaches to treatment of hepatocellular carcinoma and hepatic metastases using thermal ablation and thermosensitive liposomes.

Authors:  Mark W Dewhirst; Chelsea D Landon; Christina L Hofmann; Paul R Stauffer
Journal:  Surg Oncol Clin N Am       Date:  2013-03-13       Impact factor: 3.495

4.  Plasma membrane proteomic analysis of human osteosarcoma and osteoblastic cells: revealing NDRG1 as a marker for osteosarcoma.

Authors:  Yingqi Hua; Xiaofang Jia; Mengxiong Sun; Longpo Zheng; Lin Yin; Lijun Zhang; Zhengdong Cai
Journal:  Tumour Biol       Date:  2011-06-25

5.  A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma.

Authors:  Celina Ang; Eileen M O'Reilly; Richard D Carvajal; Marinela Capanu; Mithat Gonen; Laurence Doyle; Ronald Ghossein; Lawrence Schwartz; Gria Jacobs; Jennifer Ma; Gary K Schwartz; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2012-11

6.  Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model.

Authors:  Min-Sun Kwak; Su Jong Yu; Jung-Hwan Yoon; Sung-Hee Lee; Soo-Mi Lee; Jeong-Hoon Lee; Yoon Jun Kim; Hyo-Suk Lee; Chung Yong Kim
Journal:  J Cancer Res Clin Oncol       Date:  2015-05-20       Impact factor: 4.553

7.  NDRG1 deficiency attenuates fetal growth and the intrauterine response to hypoxic injury.

Authors:  Jacob Larkin; Baosheng Chen; Xiao-Hua Shi; Takuya Mishima; Koichi Kokame; Yaacov Barak; Yoel Sadovsky
Journal:  Endocrinology       Date:  2013-01-01       Impact factor: 4.736

8.  Endovascular Ion Exchange Chemofiltration Device Reduces Off-Target Doxorubicin Exposure in a Hepatic Intra-arterial Chemotherapy Model.

Authors:  Colin Yee; David McCoy; Jay Yu; Aaron Losey; Caroline Jordan; Terilyn Moore; Carol Stillson; Hee Jeung Oh; Bridget Kilbride; Shuvo Roy; Anand Patel; Mark W Wilson; Steven W Hetts
Journal:  Radiol Imaging Cancer       Date:  2019-09-27

9.  Identification of inositol polyphosphate 4-phosphatase type II as a novel tumor resistance biomarker in human laryngeal cancer HEp-2 cells.

Authors:  Jae-Sung Kim; Hong Shik Yun; Hong-Duck Um; Jong Kuk Park; Kee-Ho Lee; Chang-Mo Kang; Su-Jae Lee; Sang-Gu Hwang
Journal:  Cancer Biol Ther       Date:  2012-08-16       Impact factor: 4.742

10.  Key genes and drug delivery systems to improve the efficiency of chemotherapy.

Authors:  Zally Torres-Martinez; Yamixa Delgado; Yancy Ferrer-Acosta; Ivette J Suarez-Arroyo; Freisa M Joaquín-Ovalle; Louis J Delinois; Kai Griebenow
Journal:  Cancer Drug Resist       Date:  2021-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.